Treating to target in major depressive disorder: response to remission to functional recovery
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Treating to target in chronic diseases [e.g. Major Depressive Disorder (MDD)] fosters precision, consistency, and appropriateness of treatment selection and sequencing. Therapeutic target definitions/endpoints in MDD should satisfy patient-, provider-, and societal expectations. Functional recovery in depression and return to both physical and mental health are the overarching therapeutic objectives. Treating to target in MDD implies multidimensional symptomatic remission, with a particular emphasis on cognitive function and aspects of positive mental health. Several atypical antipsychotic agents (i.e. brexpiprazole, aripiprazole, quetiapine) are FDA-approved as augmentation agents in MDD. Vortioxetine, duloxetine, and psychostimulants have evidence of independent, direct, and robust effects on cognitive function in MDD. Vortioxetine is the only agent that demonstrates efficacy across multiple cognitive domains in MDD associated with functional recovery. Measurement-based care, health information technology/systems, and integrated care models (e.g. medical homes) provide requisite tools and health environments for optimal health outcomes in MDD. Achieving remission in MDD does not equate to health. Return to positive mental health as well as full functioning provide the impetus to pivot away from traditional provider-defined outcomes toward an inclusive perspective involving patient- and society-defined outcomes (i.e. optimization of human capital). As in other chronic diseases, treating to target (e.g. cognitive function) further increases the probability of achieving optimal health outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Barber, R. M., Bell, B., Bertozzi-Villa, A., Biryukov, S., Bolliger, I., Charlson, F., Davis, A., Degenhardt, L., Dicker, D., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60692-4 · Cited by 6,414
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Grand challenges in global mental health
Collins, P. Y., Patel, V., Joestl, S. S., March, D., Insel, T. R., Daar, A. S., Bordin, I. A., Costello, E. J., Durkin, M., Fairburn, C., et al. (2011) · Nature · doi:10.1038/475027a · Cited by 2,043
Antidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis
Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J. (2010) · JAMA · doi:10.1001/jama.2009.1943 · Cited by 2,009
Frank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959 · cited 1×
“The elimination of depressive symptoms has been highly associated with a more favorable illness trajectory and a reduction in illness-related measures.(13,14) Notwithstanding the emphasis on remission, a substantial percentage of adults with MDD who achieve “full remission” continue to report unfavorable health outcom…”
BackgroundThe Economic Burden of Adults With Major Depressive Disorder in the United States (2005 and 2010)
Greenberg, P. E., Fournier, A.-A., Sisitsky, T., Pike, C. T., & Kessler, R. C. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09298 · Cited by 1,779
The NIMH Research Domain Criteria (RDoC) Project: Precision Medicine for Psychiatry
Insel, T. R. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14020138 · Cited by 1,472 · cited 1×
“The pertinence of cognitive dysfunction in psychiatry across the developmental trajectory has been underscored in the rationale for creating the Research Domain Criteria (RDoC).(85,86) The RDoC matrix provides a taxonomy wherein convergent psychopathologies across all mental disorders are presented as disturbances in…”
BackgroundClinical diagnosis of depression in primary care: a meta-analysis
Mitchell, A. J., Vaze, A., & Rao, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60879-5 · Cited by 1,251 · cited 1×
“The successful management of MDD begins with timely and accurate diagnosis (the rates of false positives and false negatives in diagnosing MDD remain alarmingly high).(21) A highly reproducible finding has been that duration of untreated illness is a powerful predictor of nonresponse to antidepressant treatment.”
BackgroundCognitive Therapy vs Medications in the Treatment of Moderate to Severe Depression
DeRubeis, R. J., Hollon, S. D., Amsterdam, J. D., Shelton, R. C., Young, P. R., Salomon, R. M., O’Reardon, J. P., Lovett, M. L., Gladis, M. M., Brown, L. L., et al. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.4.409 · Cited by 989 · cited 14×
“Manual-based psychosocial treatments are unequivocally established as efficacious in the symptomatic treatment of MDD.53,54 Psychosocial treatments are often preferred by many individuals with MDD and may be preferential as first-line treatment strategies in individuals with mild baseline severity.”
BackgroundInfluential
Cited by
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
“, the five-item World Health OrganizationWell-BeingIndex) isencouraged (148, 149).”
BackgroundSelf-citationThe efficacy of vortioxetine on anhedonia in patients with major depressive disorder
Cao, B., Park, C., Subramaniapillai, M., Lee, Y., Iacobucci, M., Mansur, R. B., Zuckerman, H., Phan, L., & McIntyre, R. S. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00017 · Cited by 139
Self-citationOluboka, O. J., Katzman, M. A., Habert, J., McIntosh, D., MacQueen, G. M., Milev, R. V., McIntyre, R. S., & Blier, P. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx081 · Cited by 104
“An undiagnosed medical or psychiatric comorbidity can interfere with response to MDD treatment (McIntyre et al., 2015; Bron et al., 2016).”
BackgroundInfluentialSelf-citationVortioxetine: A Review in Cognitive Dysfunction in Depression
Frampton, J. E. (2016) · Drugs · doi:10.1007/s40265-016-0655-3 · Cited by 90
Neuropharmacological classification of antidepressant agents based on their mechanisms of action
Fasipe, O. (2018) · Archives of Medicine and Health Sciences · doi:10.4103/amhs.amhs_7_18 · Cited by 80
Metadata
- Authors
- McIntyre, R. S., Lee, Y., & Mansur, R. B.
- Venue
- CNS Spectrums
- Publisher
- Cambridge University Press (CUP)
- Published
- 2015-12
- Volume
- 20
- Issue
- S1
- Pages
- 17-31
- ISSN
- 1092-8529 (ISSN-L)
- 2165-6509
- OpenAlex
- W2388207395
- Cited by
- 84
- References
- 50
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treating to target in major depressive disorder: response to remission to functional recovery. https://app.cochat.ai/papers/10.1017/s1092852915000826
- The paper
- McIntyre, R. S., Lee, Y., & Mansur, R. B. (2015). Treating to target in major depressive disorder: response to remission to functional recovery. CNS Spectrums. https://doi.org/10.1017/s1092852915000826
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.